Ross Aldred, a 43-year-old vegan and avid gym-goer, was recently diagnosed with advanced stage four bowel cancer that had already spread to multiple organs, including his liver, spleen, lungs, and lymph nodes. The diagnosis came as a shock to Aldred, who had no significant risk factors and had maintained a healthy lifestyle, abstaining from alcohol for three years and following a plant-based diet.

Aldred first noticed "funny" lumps on his neck, which he initially assumed were related to a throat infection. Despite seeking medical help, preliminary assessments suggested a low-grade infection. However, symptoms rapidly worsened, including severe stomach pain and vomiting blood, prompting further investigations. After an endoscopy and colonoscopy, oncologists confirmed the diagnosis on June 1. The cancer was found to be a particularly aggressive subtype known as BRAF, which affects about 10% of bowel cancer patients and is more common among younger individuals.

Following his diagnosis, Aldred underwent multiple procedures, including surgery to install a stoma due to a tumor blocking his bowel. Additionally, tumors in his liver caused jaundice and raised the risk of liver failure, complicating the administration of chemotherapy. Surgeons performed a high-risk procedure involving tubes and stents to relieve liver blockages, enabling chemotherapy treatment to proceed. Aldred also experienced sepsis, a severe infection, but was able to recover quickly and return home.

Doctors say that BRAF-positive bowel cancers are often aggressive but respond well to emerging targeted therapies. Although two of the drugs involved, encorafenib and cetuximab, are available on the National Health Service (NHS), they are typically offered only after chemotherapy has failed, reducing their effectiveness. A recent international study indicated that combining these drugs with chemotherapy from the start can double life expectancy for patients, extending survival from around 15 months to 30 months, without increasing side effects significantly.

However, the full three-drug combination, proven to be more effective when used upfront, is not routinely available on the NHS and can cost private patients up to £100,000 annually, leading Aldred and his husband Matt to launch a public fundraising campaign. The appeal has attracted widespread support, raising over £246,000, with endorsements from several celebrities.

Experts emphasize that while bowel cancer has traditionally been considered a disease of older adults, cases among people under 50 have increased by approximately 50% over recent decades. Many young patients, like Aldred, are otherwise healthy and fit, challenging assumptions about risk factors. Scientists suggest that environmental factors and early life exposures—such as harmful bacteria, antibiotics, pesticides, and ultra-processed foods—may contribute to the rise in young-onset bowel cancer. One focus of recent research includes the gut toxin colibactin, produced by certain E. coli strains, which has been linked to genetic mutations associated with cancer in younger patients.

Clinicians stress that awareness of symptoms among younger people and healthcare providers is crucial, as many cases are diagnosed at advanced stages due to misattribution to less serious conditions. Aldred’s story highlights the urgent need for improved access to innovative treatments and earlier detection strategies, as well as ongoing research into the underlying causes of bowel cancer in younger populations.